Scope and Claims Analysis for US Patent 8,679,094: Deployable Intravesical Elastic Drug Device
US 8,679,094 claims a bladder-deployable, elastic, retention-shaped drug delivery device that is “wholly deployable within the bladder,” passes the urethra in a low-profile deployment state, then transforms to a retention configuration that prevents voiding and blocks entry into the ureteral orifices. The core claim set ties together (1) structural/biomechanical constraints on the elastic body and deformation forces, (2) drug formulation format (tablets/solid drug units as discrete units), and (3) release mechanism options (osmotic pressure and/or diffusion), with multiple dependent claim fallbacks that narrow by geometry, materials, tablet morphology, and drug actives.
What is the claim architecture and what does it cover?
The independent claims define the protected product concept; dependent claims carve out narrower embodiments.
Independent claim coverage (high-level)
- Claim 1 defines a “medical device” with an elastic body that:
- has a retention shape configured to provide intravesical mobility and prevent voiding through the urethra; and
- has dimensions, buoyancy, or both configured to exclude the device from entering the orifices of the ureters; and
- houses a drug formulation in the form of a plurality of tablets.
- Claim 23 and Claim 25 define “drug delivery device” variants that emphasize:
- deformability between a urethral deployment shape and a bladder retention shape;
- strict retention geometry limits (≤ 6 cm maximum dimension uncompressed); and
- strict handling force limits (< 1 N acting force when compressed to ≤ 3 cm maximum dimension); and
- solid drug units with circular flat end faces and cylindrical side wall; and
- in Claim 25, a specific retention geometry with two sub-circles and shared larger arch.
Dependent claim funneling
Claim 1 is the broadest base and is narrowed by at least four claim-value “axes”:
- Mechanical/biomechanical constraints
- Compression force ceiling: <1 N at compressed size 3 cm (Claim 2) and at 1.5 cm (Claim 3)
- Retention size ceiling: <10 cm (Claim 4), and tighter <5 cm (Claim 5)
- Urethral/passage geometry fit constraint via an “isosceles triangle” opening exclusion (Claim 6)
- Low-profile deployed outer diameter: < about 4 mm (Claim 7)
- Dry density range/ceiling: <1.5 g/mL (Claim 8) and 0.5 to 1.3 g/mL (Claim 9)
- Drug release mechanism options
- Osmotic pressure release (Claim 11)
- Diffusion release (Claim 12)
- Elastic body material
- Water-permeable elastomer (Claim 13)
- Silicone, poly(urethane), or combinations (Claim 14)
- Drug identity and tablet morphology
- Drug category: anesthetic or analgesic (Claim 15)
- Specific example actives: lidocaine (Claim 16), oxybuthynin (Claim 17), gemcitabine (Claim 18), trospium (Claim 19)
- Tablet geometry: circular flat ends and cylindrical side wall (Claim 20), aspect ratio height:width > 1:1 (Claim 21)
Claims 23 and 25 add further “hard” constraints on retention deformation and retention shape complexity but are built on the same device concept.
What are the claim elements that define infringement risk?
A. Elastic body retention geometry and functional exclusions
The most infringement-relevant portion is the retention shape being configured to:
- Prevent voiding through the urethra while in the bladder (Claim 1);
- Provide intravesical mobility (Claim 1); and
- Be excluded from entering the ureteral orifices, via dimensions, buoyancy, or both (Claim 1).
Claims 23 and 25 tighten structural bounds:
- Retention shape maximum dimension in any direction: ≤ 6 cm when uncompressed (Claim 23 and Claim 25).
- Claim 25 adds a specific retention geometry: two sub-circles, each with smaller arches sharing a common larger arch.
Landscape implication: a competitor can reduce risk only by changing one of the required functional exclusions (ureter orifice exclusion) or by departing from the explicit geometric constraints and/or deformation force limits.
B. Deformation limits and compressive force ceiling
Across Claims 2 and 3 (and mirrored in Claim 23), the device must be:
- < 1 N maximum acting force when compressed:
- to a 3 cm maximum dimension (Claim 2); and
- to a 1.5 cm maximum dimension (Claim 3).
- Claim 23 also includes: < 1 N maximum acting force when compressed from retention shape to a shape with max dimension ≤ 3 cm.
Landscape implication: products that compress substantially more forcefully, or require higher insertion loads, fall outside these narrow dependent claims; but the independent structural/functional claims (Claim 1) still leave room unless the court reads other constraints into the independent claim via claim construction.
C. Deployment low profile requirement
Claim 7 sets:
- outer diameter in one direction < about 4 mm for the elastically deformable low-profile state.
Claim 6 includes a geometric “exclusion”:
- retention-shape device cannot fit through an opening shaped like an isosceles triangle with two sides 2.8 cm and one side 3.3 cm.
Landscape implication: design-around can focus on retention geometry and deployed diameter; but these dimensions are detailed enough that simple “similar-sized” devices may still be captured if within the bounds and if configured to meet the functional retention exclusions.
D. Drug formulation as discrete tablets/solid units
The device “houses” drug in:
- plurality of tablets (Claim 1), or
- one or more solid drug units (Claims 23 and 25), with:
- circular flat end faces and
- cylindrical side wall (Claim 23).
Claim 20 and 21 further nail tablet geometry:
- circular flat end faces and cylindrical side wall (Claim 20);
- aspect ratio height:width > 1:1 (Claim 21).
Claim 10: drug formulation mass ≤ 275 mg (Claim 10).
Landscape implication: sustained-release reservoirs or monolithic drug forms that do not use these discrete tablet/solid unit forms can be outside dependent claims, but the independent claim language still calls out “plurality of tablets” in Claim 1. A competitor can reduce exposure by using a different drug form factor not meeting the “plurality of tablets” requirement.
E. Release mechanism options
Claim 11 and Claim 12 provide release mechanism dependent routes:
- osmotic pressure for solubilized drug release; and/or
- diffusion for solubilized drug release.
Landscape implication: if a competitor uses a wholly different release mechanism (e.g., hydrogel swelling erosion-based kinetics) and avoids meeting these dependent limitations, it may avoid those dependent claims, but it may still face risk under broader device elements if the dependent features are not required by the independent claims.
F. Materials and density bounds
- Water-permeable elastomeric material (Claim 13).
- Silicone and/or poly(urethane) (Claim 14).
- Dry state density:
- < 1.5 g/mL (Claim 8)
- 0.5 to 1.3 g/mL (Claim 9)
Landscape implication: materials selection and density can support design-around, especially if they breach the density range or move away from water-permeable elastomers.
G. Drug active specificity
Claim 15 sets a category (anesthetic or analgesic). Claims 16-19 identify example actives including:
- lidocaine (Claim 16),
- oxybutynin (Claim 17),
- gemcitabine (Claim 18),
- trospium (Claim 19).
Landscape implication: the patent is not restricted to one indication; it covers the device architecture coupled with any “at least one drug” that satisfies the listed dependent claim options. For any given active, enforceability risk concentrates around whether the product uses the claimed tablet/retention architecture and the dependent limitations.
What do the numeric limitations mean for scope?
Below is the numeric “gating” imposed by the claim text.
Key numeric constraints (Claims 2, 3, 4, 5, 7, 8, 9, 10, 23)
| Parameter |
Limit in claims |
Where |
| Max acting force when compressed |
< 1 N |
Claims 2, 3, 23 |
| Max device dimension during compression |
3 cm (Claim 2) or 1.5 cm (Claim 3) or ≤ 3 cm (Claim 23) |
Claims 2, 3, 23 |
| Max retention dimension (uncompressed) |
< 10 cm |
Claim 4 |
| Max retention dimension (uncompressed) |
< 5 cm |
Claim 5 |
| Low-profile deployed outer diameter |
< about 4 mm |
Claim 7 |
| Max retention dimension for deformable deployment/retention variant |
≤ 6 cm |
Claim 23 (and Claim 25) |
| Dry density ceiling |
< 1.5 g/mL |
Claim 8 |
| Dry density range |
0.5 to 1.3 g/mL |
Claim 9 |
| Drug mass in formulation |
≤ 275 mg |
Claim 10 |
Structural geometry constraints
- Ureter orifice exclusion by dimensions and/or buoyancy (Claim 1)
- Urethral passage exclusion using triangle-fit constraint (Claim 6)
- Tablet geometry: circular flat ends + cylindrical side wall (Claims 20, 23)
- Tablet aspect ratio height:width >1:1 (Claim 21, Claim 24)
- Retention shape with two sub-circles and shared larger arch (Claim 22, Claim 25)
How broad is the device concept vs. how narrow the dependent claims?
Claim 1 breadth profile
Claim 1 combines:
- a functional retention concept (prevent voiding + ureter orifice exclusion),
- a mechanical concept (elastic body with retention shape and intravesical mobility),
- and a formulation concept (plurality of tablets).
But Claim 1 does not in its text automatically require every numeric bound from dependent claims. Those bounds appear in dependents (force, dimensions, deployed diameter, density, etc.).
Claims 23 and 25 breadth profile
Claims 23 and 25 are more explicitly constrained:
- bladder deployment/retention via deformability;
- retention max dimension ≤ 6 cm;
- force <1 N at compressed size ≤3 cm (directly stated);
- solid drug units with specific end-face and side-wall shape; and
- Claim 25 adds the two sub-circle retention geometry.
Net effect: Claim 23/25 are narrower than Claim 1, but they create strong “design lock” targets because they define deformation, maximum dimensions, and tablet geometry.
What is the likely patent landscape around this claim set?
Without prosecution history, family status, continuations, and citation data, the landscape can only be characterized at the conceptual level implied by the claim structure.
Likely technology clusters implicated by the claims
-
Intravesical retention devices with elastic deformability
- Key differentiators in the claim are deformation force (<1 N) and deployed outer diameter (<4 mm) while providing urethral passage and bladder retention.
-
Drug-in-device bladder platforms using osmotic pressure and diffusion
- The claims cover solubilized drug release by osmotic pressure and/or diffusion, indicating compatibility with classic controlled-release architectures (osmotic delivery, diffusion-controlled release) packaged inside a bladder-retention body.
-
Tablet/solid-unit format within a retention device
- The “plurality of tablets” and “solid drug units with circular flat end faces and cylindrical side wall” suggest the formulation is not a liquid reservoir or bulk matrix, but discrete units.
-
Actives spanning symptom control and anticancer use
- Listed actives include lidocaine, oxybutynin, trospium (uro/spasm or analgesia), and gemcitabine (oncology). That breadth suggests the same mechanical platform is used across different therapeutic payloads.
Practical implication for competitors
-
Highest litigation risk products are those that:
- deploy wholly within the bladder,
- use an elastic retention geometry that prevents voiding and avoids ureteral orifice entry,
- use discrete cylindrical tablets/solid units,
- meet the deformation force/dimension gates, and
- deliver solubilized drug by osmotic pressure and/or diffusion.
-
Lower risk options (relative, based strictly on claim reading) include:
- reservoir-based or monolithic drug formats (not “plurality of tablets” / not cylindrical solid units with the specific end-face geometry),
- non-elastic or retention mechanisms that do not use the specified deployment-to-retention deformation profile,
- designs that rely on different release mechanisms not matching osmotic pressure/diffusion language (while still potentially risking under independent claims depending on claim construction).
What are the claim-by-claim scope signals that matter for freedom-to-operate?
Claim 1 (core)
- “wholly deployable within the bladder”
- “well tolerated by the patient” (device is described by patient acceptance; not a dimensional or material parameter)
- elastic body with retention shape:
- intravesical mobility
- prevent voiding through urethra
- exclude from entering ureter orifices by dimensions and/or buoyancy
- houses drug formulation as plurality of tablets comprising at least one drug
Claims 2-10 (engineering gates)
- force at compression sizes (<1 N at 3 cm and 1.5 cm)
- retention size caps (<10 cm and <5 cm)
- retention geometry exclusion for urethral passage (triangle fit)
- deployed outer diameter (< about 4 mm)
- dry density caps (<1.5 g/mL; 0.5 to 1.3 g/mL)
- drug mass cap (≤275 mg)
Claims 11-14 (release + materials)
- osmotic pressure release (Claim 11)
- diffusion release (Claim 12)
- water-permeable elastomer (Claim 13)
- silicone/polyurethane (Claim 14)
Claims 15-21 (payload and tablet morphology)
- anesthetic/analgesic category (Claim 15)
- example actives including lidocaine/oxybuthynin/gemcitabine/trospium
- tablet face/side-wall geometry and aspect ratio >1:1
Claims 22-25 (retention shape elaboration + tighter drug-unit form)
- retention shape with two sub-circles and shared arch (Claims 22 and 25)
- explicit deformability + retention dimension ≤6 cm and force <1 N at compressed ≤3 cm (Claims 23 and 25)
- solid drug units with circular flat ends and cylindrical side wall and aspect ratio >1:1 (Claims 23, 24)
Key Takeaways
- US 8,679,094 protects an intravesical, fully deployable elastic retention device that prevents voiding and excludes ureter orifice entry, combined with discrete tablet/solid-unit drug payloads.
- The most enforceable boundaries are the deformation/handling gates: <1 N acting force when compressed to 3 cm (and 1.5 cm) and a deployed state with < about 4 mm outer diameter.
- The most specific structural limits are retention max dimension caps (≤6 cm in Claims 23/25; <5 cm and <10 cm in Claims 5/4) and tablet morphology (cylindrical side wall with circular flat ends; aspect ratio height:width >1:1).
- The release scope depends on dependent limitations covering osmotic pressure and diffusion release of solubilized drug.
- Retention-shape geometry (two sub-circles, shared larger arch) is a targeted narrowing feature that can separate close designs under Claim 25 and Claim 22.
FAQs
-
What feature most directly limits design-around opportunities?
The combination of bladder deployment with urethral passage plus retention configured to prevent voiding and exclude ureteral orifices, paired with the tablet/solid-unit payload format.
-
Which constraints are hardest to satisfy without testing?
The force requirements: maximum acting force <1 N at specified compression dimensions (3 cm and 1.5 cm) and, in Claims 23/25, compression from retention to ≤3 cm.
-
Can a different drug release mechanism avoid dependent claims?
The dependent claims explicitly recite release by osmotic pressure or diffusion; moving away from those mechanisms can avoid those dependent limitations, while the core device scope still depends on the independent claim elements.
-
Does the patent cover multiple drug actives?
The dependent claims list examples including lidocaine, oxybuthynin, gemcitabine, and trospium, tied to the same device architecture.
-
Is the retention shape geometry a required element in the broadest claim?
Claim 1 requires a retention shape with functional outcomes (prevent voiding and exclude ureter entry) but does not, in its text, require the two-sub-circle geometry that appears in Claim 22 and Claim 25.
References
[1] United States Patent 8,679,094.
